BIBBINSTRUMENTS AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.6 SEK | +0.22% |
|
+0.66% | +45.57% |
| 03/05 | BiBBInstruments AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 18/04 | BiBBInstruments Secures Patent for EndoDrill in India | MT |
| Sales 2021 | 16K 1.48K 123K | Sales 2022 | - | Capitalization | 131M 12.11M 1.01B |
|---|---|---|---|---|---|
| Net income 2021 | -10M -925K -77.14M | Net income 2022 | -11M -1.02M -84.86M | EV / Sales 2021 | 9,916 x |
| Net cash position 2021 | 6.96M 644K 53.72M | Net cash position 2022 | 13.45M 1.24M 104M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-16.1
x | P/E ratio 2022 |
-10.8
x | Employees | 3 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.22% | ||
| 1 week | +0.66% | ||
| Current month | +0.88% | ||
| 1 month | +2.91% | ||
| 3 months | +50.33% | ||
| 6 months | +94.92% | ||
| Current year | +45.57% |
1 week
4.31
4.90
1 month
4.075.00
Current year
2.605.00
1 year
2.205.00
3 years
1.9011.20
5 years
1.9011.20
10 years
1.9019.10
| Managers | Title | Age | Since |
|---|---|---|---|
Charles Walther
FOU | Founder | 50 | 01/13/01 |
| Chief Executive Officer | 57 | 01/13/01 | |
| Chief Tech/Sci/R&D Officer | 38 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 60 | 01/17/01 | |
| Director/Board Member | 69 | 01/13/01 | |
| Chief Executive Officer | 57 | 01/13/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 4.6 | +0.22% | 13,758 |
| 02/24/02 | 4.59 | +0.66% | 3,576 |
| 30/24/30 | 4.56 | +0.88% | 11,689 |
| 29/24/29 | 4.52 | -1.09% | 7,903 |
| 26/24/26 | 4.57 | +1.33% | 20,363 |
End-of-day quote NORDIC GROWTH MARKET, May 03, 2024
More quotes
BibbInstruments AB is a Sweden-based medical technology company. It develops and sales biopsy instruments, which are based on technology platform EndoDrill. The drill function enables early cancer diagnosis, especially in deep skin tissues. The portfolio includes EndoDrill GI Upper for stomach biopsy, EndoDrill GI Lower for intestinal biopsy, EndoDrill GI Lung for lung biopsy, EndoDrill Therapy to pass displacements in different organs for placement of conductors, balloons and stents for treatment, EndoDrill Needle for breasts biopsy, as well as EndoDrill Model X for multiple areas and falls under independent research project. Products are distributed to hospitals with endoscopy specialistsâ centers and surgical wards. The Companyâs primary distribution focus is Scandinavian countries.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +45.57% | 11.3M | |
| -42.33% | 2.84B | |
| +17.00% | 1.85B | |
| -0.51% | 1.66B | |
| +27.15% | 1.26B | |
| -13.90% | 989M | |
| -21.76% | 896M | |
| -2.72% | 757M | |
| -23.95% | 633M | |
| +6.84% | 500M |
- Stock Market
- Equities
- BIBB Stock
